Zobrazeno 1 - 10
of 1 035
pro vyhledávání: ''
Autor:
D. Feng, David Maag, Banu Arun, Shannon Puhalla, S. Bhattacharya, Madan Gopal Kundu, N. Khandelwal, Christine K. Ratajczak, Hans Wildiers, Bruce A. Bach, Véronique Diéras, J.P. Ayoub, Hyo S. Han, Michael Friedlander, Bella Kaufman
Publikováno v:
Annals of Oncology. 33:299-309
BACKGROUND: In the BROCADE3 trial, addition of the poly(ADP-ribose) polymerase inhibitor, veliparib, to carboplatin/paclitaxel improved progression-free survival (PFS) (hazard ratio 0.71, 95% confidence interval 0.57-0.88; P = 0.002) in patients with
Autor:
Gerhard Held, Viola Poeschel, Lorenz Trümper, Julia Richter, Karoline Koch, Andreas Rosenwald, Marita Ziepert, Annette M. Staiger, Sarah Reinke, W. Klapper, Rex Au-Yeung, Rainer Spang, Markus Loeffler, Giorgio Alberto Croci, Ilske Oschlies, Bettina Altmann, German Ott
Publikováno v:
Annals of Oncology. 32:1400-1409
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with respect to outcome. Features of the tumor microenvironment (TME) are associated with prognosis when assessed by gene expression profiling. However, it is uncertain whether assessme
Autor:
L.A. Emens, S. Adams, C.H. Barrios, V. Diéras, H. Iwata, S. Loi, H.S. Rugo, A. Schneeweiss, E.P. Winer, S. Patel, V. Henschel, A. Swat, M. Kaul, L. Molinero, S.Y. Chui, P. Schmid
Publikováno v:
Annals of Oncology. 32:983-993
Background Guidelines recommend atezolizumab plus nab-paclitaxel (A + nP) for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer expressing programmed death-ligand 1 (PD-L1) on tumor-infiltrating immun
Autor:
G. Speranza, Helge Bischoff, Enriqueta Felip, Steven Francis Powell, Shirish M. Gadgeel, Maximilian Hochmair, F. De Angelis, Manuel Domine, Emilio Esteban, Edward B. Garon, Delvys Rodriguez-Abreu, Takayasu Kurata, J. Yang, N. Peled, Rina Hui, Martin Reck, S. Cheng, M.C. Pietanza, Fabricio Souza, M.C. Garassino, Michael Boyer
Publikováno v:
Annals of Oncology. 32:881-895
Background In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with previ
Autor:
Sonal Shad, William Fraser Symmans, Debu Tripathy, Lamorna Brown-Swigart, LJ Esserman, Jane Perlmutter, V. Valero, Rebekah Gould, Gregor Krings, Judy C. Boughey, Jodi M. Carter, M. van der Noordaa, Gillian L. Hirst, L.J. van 't Veer, Christina Yau, Douglas Yee, Lajos Pusztai, Tufia C. Haddad, Kathy S. Albain, Molly Klein, Lili Du, MC Liu, Rita Nanda, Claudine Isaacs, Richard Schwab, Amy Jo Chien, Donald A. Berry, Rachel M. Layman, AM DeMichele, Isabelle Bedrosian, Sara J. Venters, Nola M. Hylton
Publikováno v:
Annals of Oncology. 32:642-651
BACKGROUND We proposed that a test for sensitivity to the adjuvant endocrine therapy component of treatment for patients with stage II-III breast cancer (SET2,3) should measure transcription related to estrogen and progesterone receptors (SETER/PR in
Autor:
Dirk Waldschmidt, J-B. Bachet, Lawrence Fong, J. Tabernero, Michele Reni, H-M. Chang, Sara Lonardi, G. Cole, Margaret A. Tempero, Andrew Eugene Hendifar, D-Y. Oh, L.C. Tsao, Teresa Macarulla, Danelle F. James, E. Van Cutsem, Juan Maurel, Lisa M. Coussens, Naureen Starling, Rocio Garcia-Carbonero
Publikováno v:
Scientia
Ibrutinib; Metastatic pancreatic adenocarcinoma; Phase III Ibrutinib; Adenocarcinoma de páncreas metastásico; Fase III Ibrutinib; Adenocarcinoma de pàncrees metastàtic; Fase III First-line treatment of metastatic pancreatic ductal adenocarcinoma
Autor:
N. Pardo Aranda, Clarisse Audigier-Valette, Juergen Wolf, David Vicente, Scott J. Antonia, Dimple Pandya, Kazuhiko Nakagawa, David R. Spigel, Solange Peters, Alexander Luft, M. Shi, Ying Cheng, O. Juan-Vidal, Scott N. Gettinger, Martin Reck, J. Fairchild, Parul Doshi, Tudor-Eliade Ciuleanu, Leora Horn, Han Chang, Christine Baudelet, H. Zhang
Publikováno v:
ANNALS OF ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Patients with relapsed small-cell lung cancer (SCLC) have few treatment options and dismal survival. Phase I/II data show activity of nivolumab in previously treated SCLC.CheckMate 331 is a randomized, open-label, phase III trial of nivolumab versus
Autor:
Y.S. Park, Wonyoung Kang, T.S. Sohn, S.H. Park, D.Y. Zang, Artist investigators, S.J. Kim, Ji Yeong An, J.H. Ji, J.H. Lee, S.T. Kim, Dongbok Shin, J.W. Lee, Min-Gew Choi, J.O. Park, S.Y. Oh, J.M. Bae, In Gyu Hwang, J.Y. Hong, Dong Hui Lim, Jeong Il Yu, Jung-Hun Kang, Kyeongdeok Kim, H.Y. Lim
Publikováno v:
Annals of Oncology. 32:368-374
Background Adjuvant chemotherapy and chemoradiotherapy are some of the standards of care for gastric cancer (GC). The Adjuvant chemoRadioTherapy In Stomach Tumors (ARTIST) 2 trial compares two adjuvant chemotherapy regimens and chemoradiotherapy in p
Autor:
William A. Wegener, David M. Goldenberg, RL Moroose, Joyce O'Shaughnessy, Dejan Juric, Aditya Bardia, Sara M. Tolaney, Jennifer R. Diamond, Vandana G. Abramson, Ingrid A. Mayer, Pius Maliakal, Linda T. Vahdat, T. Goswami, Kevin Kalinsky, Robert M. Sharkey, Q. Hong
Publikováno v:
Ann Oncol
Background Trophoblast cell-surface antigen-2 (Trop-2) is expressed in epithelial cancers, including hormone receptor-positive (HR+) metastatic breast cancer (mBC). Sacituzumab govitecan (SG; Trodelvy®) is an antibody–drug conjugate composed of a
Autor:
Tianyu Li, Nan Lin, Elizabeth V. Lawler, Julieta Leone, Eric P. Winer, Sara M. Tolaney, Luke Walker, O. Metzger Filho, Rachel A. Freedman, Jerry Younger, William T. Barry, Lorenzo Trippa, Zhenying Tan-Wasielewski, Ian E. Krop
Publikováno v:
Annals of Oncology. 31:1231-1239
Background Brain metastases are frequent in HER2-positive breast cancer. ONT-380 (tucatinib) is a potent selective inhibitor of HER2 with intracranial activity in preclinical models. Patients and methods This was a phase I study of tucatinib with tra